- 17
- 1 318
founders in biotech
Germany
เข้าร่วมเมื่อ 18 เม.ย. 2022
As a founder, Serghei experienced the challenges of building a company in the fragmented biotech ecosystem.
Giving back and connecting the biotech ecosystem has become his mission.
Giving back and connecting the biotech ecosystem has become his mission.
Maria Soloveychik on synthetic biology for discovery of protein interaction modulators
Maria Soloveychik is the co-founder and CEO of SyntheX, a therapeutics company accelerating drug discovery through synthetic biology. SyntheX, founded in 2016 and headquartered in San Francisco, advances its own oncology pipeline and partners in external discovery collaborations. Maria holds a PhD in Molecular Genetics from the University of Toronto, where her research uncovered novel pathways linking metabolism and epigenetic signaling. As a former research scientist at the Structural Genomics Consortium, her work contributed to determining numerous protein structures and identifying several promising drug candidates.
Contact to Maria Soloveychik: www.linkedin.com/in/maria-soloveychik
Listen on: Apple Podcast: apple.co/43Zn1Hj
TH-cam Music: bit.ly/4fiFnsT
Spotify: spoti.fi/3qqfBiB
Amazon Music: amzn.to/3DO2kn1
Visit our website: foundersinbiotech.com
#biotech #innovation #inspiration #entrepreneur #Therapeutics
Contact to Maria Soloveychik: www.linkedin.com/in/maria-soloveychik
Listen on: Apple Podcast: apple.co/43Zn1Hj
TH-cam Music: bit.ly/4fiFnsT
Spotify: spoti.fi/3qqfBiB
Amazon Music: amzn.to/3DO2kn1
Visit our website: foundersinbiotech.com
#biotech #innovation #inspiration #entrepreneur #Therapeutics
มุมมอง: 31
วีดีโอ
Christoph Lengauer on building visionary biotech companies
มุมมอง 134หลายเดือนก่อน
Christoph Lengauer has contributed to the development of 10 FDA-approved cancer medicines. Christoph is Chief Scientific Officer and a co-founder of Curie.Bio, where he and his team co-pilot seed-stage companies to help founders to achieve series A. Prior to Curie, Christoph ideated, founded, and built several life science companies as Partner at Third Rock Ventures, including Blueprint Medicin...
Deep dive into business development in biotech with James Lee
มุมมอง 6710 หลายเดือนก่อน
Business development is an essential process for biotech companies to build relationships with partners and create value from the deal structures that are based on science. We are taking a deep dive with James Lee into the mechanics and the framework that James uses for business development. James founded Bridge Biotherapeutics Inc. in 2015 and he currently serves as the CEO. Bridge has been re...
James Lee on the vital role of business development for biotech companies
มุมมอง 10110 หลายเดือนก่อน
Description: James Lee received his B.S and M.S. in Structural Biology from Seoul National University, he held various roles in research, research planning, and business development at LG Chem. In year 2000, James co-founded Crystal Genomics where he led fundraising and business development activities. In 2008, he founded Rexbio, an early-stage biotech startup specialized in discovering and dev...
Yaniv Erlich on building a scalable platform to discover next-gen RNA therapeutics
มุมมอง 68ปีที่แล้ว
Prof. Yaniv Erlich received his bachelor’s degree from Tel-Aviv University, Israel in 2006 and a PhD from the Watson School of Biological Sciences at Cold Spring Harbor Laboratory in 2010. Yaniv Erlich was an Associate Professor of Computer Science at Columbia University and was a PI at the Whitehead Institute, MIT. His research interests are computational human genetics. Yaniv has been an advi...
Kiyoshi Takayama on targeting challenging GPCRs using monoclonal antibodies
มุมมอง 38ปีที่แล้ว
Kiyoshi Takayama has received a Ph.D. in pharmaceutical science from the University of Tokyo. After his PhD he worked for more than 12 years as a research scientist at Taisho Pharmaceutical, Japan, where he was involved in the development of G-protein coupled receptors (GPCRs) assay and the conducting of various drug discovery programs for chronic inflammation and chronic obstructive pulmonary ...
David Younger on how synthetic biology helps to identify molecular glues
มุมมอง 982 ปีที่แล้ว
David Younger is a bioengineer and started his biotech journey directly after his PhD. David’s scientific research was focused on the application of synthetic biology techniques for high-throughput screening of protein-protein interactions. In 2017 David co-founded A-Alpha Bio as a spin-out from the University of Washington. A-Alpha Bio applies synthetic biology to reprogram yeast mating and ge...
Elaine Hamm on overcoming the “shiny object syndrome” in biotech
มุมมอง 402 ปีที่แล้ว
The path from the lab bench to market in biotech has many hurdles and lots of opportunities. Sometimes too many. Elaine Hamm has experienced all stages of bringing innovation from academia to a successful company and products. She shares a valuable framework on how to overcome the “shiny object syndrome” in biotech. Elaine did her graduate and post-graduate studies in biochemistry and microbiol...
Deep dive into targeted protein degradation and PROTACs with Alessio Ciulli
มุมมอง 3232 ปีที่แล้ว
Targeted protein degradation, TPD, is a new and disruptive therapeutic approach for development of medicines. TPD opened doors to develop small molecules to drug the ‘undruggable’. Instead of blocking the function of a protein, small molecules can lead to the degradation of the disease causing protein. Small molecules that have these properties are called proteolysis targeting chimeras, PROTACs...
Alessio Ciulli on the next level of small molecules as thrapeutics: PROTACs I founders in biotech
มุมมอง 1472 ปีที่แล้ว
Targeted protein degradation, or TPD, is a new and disruptive therapeutic approach for development of medicines. TPD utilizes the design of small molecules that can address disease-causing proteins that are highly challenging to drug. We discuss with @Alessio Ciulli about his exceptional career path as well as about the transformative potential of so-called PROTACs for TPD. Alessio Ciulli studi...
ultradeep chemoproteomics and machine learning for covalent drug discovery by MARK TEBBE
มุมมอง 1552 ปีที่แล้ว
Mark Tebbe started his career as an organic chemist and later had senior positions at Lilly. After 16 years of a successful career in pharma, Mark started his biotech journey. He has been leading drug discovery at multiple biotech companies including Forma Therapeutics, Quatet Medicine, and Quench Bio. Mark is also the co-inventor of Telaprevir. Telaprevir is an inhibitor of the serine protease...
building a mission-driven biotech company by CARLO BERTOZZI | founders in biotech
มุมมอง 592 ปีที่แล้ว
building a mission-driven biotech company by CARLO BERTOZZI | founders in biotech
Promo-SM
Hi, Really nice discussion over protacs and degraded protein degradation. I have a query regarding different efficiency of protacs with same CRL and for same substrate. Is the difference in efficiency comes from protacs binding to the CRLs in such a way that it promotes more and less binding of k48 polyubiquitin to the substrate? Does it play in orienting ubiquitin linkage?
Thank you for hosting me! I had such a great time.